Needham Reiterates Buy on Biogen, Maintains $294 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia reiterates a Buy rating on Biogen (NASDAQ:BIIB) and maintains a $294 price target.
July 26, 2024 | 7:54 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Ami Fadia reiterates a Buy rating on Biogen and maintains a $294 price target.
The reiteration of a Buy rating and the maintenance of a $294 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100